Proteomics in hypertension and other cardiovascular diseases

Annals of Medicine

Volumn 44, Issue SUPPL. 1, 2012, Pages

  Delles, Christian ^a   Neisius, Ulf ^a   Carty, David M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Capillary electrophoresis; cardiovascular disease; hypertension; mass spectrometry; preeclampsia; proteomics

Indexed keywords

ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER;

BODY FLUID; CARDIOVASCULAR DISEASE; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; GENOMICS; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MASS SCREENING; METABOLOMICS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEOMICS; REVIEW; RISK FACTOR;

ANIMALS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYPERTENSION; PRE-ECLAMPSIA; PREGNANCY; PROTEOMICS; RISK FACTORS;

EID: 84862533418     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2012.660494     Document Type: Review

References (67)

1. Lawes CM, Vander HS, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513-8. (Pubitemid 351626187)
2. Dominiczak AF, Herget-Rosenthal S, Delles C, Fliser D, Fournier I, Graber A, et al. Systems biology to battle vascular disease. Nephrol Dial Transplant. 2010;25:1019-22.
3. Anderson NL, Anderson NG. Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis. 1998;19:1853-61. (Pubitemid 28392230)
4. Schiffer E, Mischak H, Theodorescu D, Vlahou A. Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform. World J Urol. 2008;26:67-74.
5. Schiffer E, Mischak H, Novak J. High resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with MS. Proteomics. 2006;6:5615-27. (Pubitemid 44683225)
6. Kolch W, Mischak H, Pitt AR. The molecular make-up of a tumour: proteomics in cancer research. Clin Sci (Lond). 2005;108:369-83. (Pubitemid 40685668)
7. Mullen W, Delles C, Mischak H. Urinary proteomics in the assessment of chronic kidney disease. Curr Opin Nephrol Hypertens. 2011;20:654-61.
8. Mischak H, Delles C, Klein J, Schanstra JP. Urinary proteomics based on capillary electrophoresis-coupled mass spectrometry in kidney disease: discovery and validation of biomarkers, and clinical application. Adv Chronic Kidney Dis. 2010;17:493-506.
9. Mischak H, Massy ZA, Jankowski J. Proteomics in uremia and renal disease. Semin Dial. 2009;22:409-16.
10. Feinleib M, Garrison RJ, Fabsitz R, Christian JC, Hrubec Z, Borhani NO, et al. The NHLBI twin study of cardiovascular disease risk factors: methodology and summary of results. Am J Epidemiol. 1977;106:284-5.
11. Mongeau JG, Biron P, Sing CF. The influence of genetics and household environment upon the variability of normal blood pressure: the Montreal Adoption Survey. Clin Exp Hypertens A. 1986;8:653-60. (Pubitemid 16051449)
12. Staessen JA, Wang J, Bianchi G, Birkenhager WH. Essential hypertension. Lancet. 2003;361:1629-41. (Pubitemid 36579003)
13. Padmanabhan S, Delles C, Dominiczak AF. Genetic factors in hypertension. Arch Med Sci. 2009;5(2A):S212-9.
14. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991;121:1244-63.
15. Tunon J, Martin-Ventura JL, Blanco-Colio LM, Lorenzo O, Lopez JA, Egido J. Proteomic strategies in the search of new biomarkers in atherothrombosis. J Am Coll Cardiol. 2010;55:2009-16.
16. Gerszten RE, Asnani A, Carr SA. Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics. Circ Res. 2011;109:463-74.
17. Mischak H, Allmaier G, Apweiler R, Attwood T, Baumann M, Benigni A, et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med. 2010;2:46ps42.
18. Lowenthal MS, Mehta AI, Frogale K, Bandle RW, Araujo RP, Hood BL, et al. Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem. 2005;51:1933-45. (Pubitemid 41368193)
19. Granger J, Siddiqui J, Copeland S, Remick D. Albumin depletion of human plasma also removes low abundance proteins including the cytokines. Proteomics. 2005;5:4713-8. (Pubitemid 43016893)
20. Tanaka K, Tsugawa N, Kim YO, Sanuki N, Takeda U, Lee LJ. A new rapid and comprehensive peptidome analysis by one-step direct transfer technology for 1-D electrophoresis/MALDI mass spectrometry. Biochem Biophys Res Commun. 2009;379:110-4.
21. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631-9. (Pubitemid 44969122)
22. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358:2107-16. (Pubitemid 351679597)
23. Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, Lonn E, et al. Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2006;114:201-8. (Pubitemid 44297113)
24. Good DM, Thongboonkerd V, Novak J, Bascands JL, Schanstra JP, Coon JJ, et al. Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J Proteome Res. 2007;6:4549-55.
25. Haubitz M, Wittke S, Weissinger EM, Walden M, Rupprecht HD, Floege J, et al. Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int. 2005;67:2313-20. (Pubitemid 41623391)
26. Wittke S, Haubitz M, Walden M, Rohde F, Schwarz A, Mengel M, et al. Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients. Am J Transplant. 2005;5:2479-88.
27. Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 2006;7:230-40. (Pubitemid 43286453)
28. Theodorescu D, Schiffer E, Bauer HW, Douwes F, Eichhorn F, Polley R, et al. Discovery and validation of urinary biomarkers for prostate cancer. Proteomics Clin Appl. 2008;2:556-70. (Pubitemid 351566263)
29. Mischak H, Coon JJ, Novak J, Weissinger EM, Schanstra JP, Dominiczak AF. Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. Mass Spectrom Rev. 2009;28:703-24.
30. Dakna M, He Z, Yu WC, Mischak H, Kolch W. Technical, bioinformatical and statistical aspects of liquid chromatographymass spectrometry (LC-MS) and capillary electrophoresis-mass spectrometry (CE-MS) based clinical proteomics: a critical assessment. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:1250-8.
31. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119:2408-16.
32. Zimmerli LU, Schiffer E, Zurbig P, Good DM, Kellmann M, Mouls L, et al. Urinary proteomic biomarkers in coronary artery disease. Mol Cell Proteomics. 2008;7:290-8. (Pubitemid 351298443)
33. von zur Muhlen C, Schiffer E, Zuerbig P, Kellmann M, Brasse M, Meert N, et al. Evaluation of urine proteome pattern analysis for its potential to reflect coronary artery atherosclerosis in symptomatic patients. J Proteome Res. 2009;8:335-45.
34. Delles C, Schiffer E, von Zur Muhlen C, Peter K, Rossing P, Parving HH, et al. Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. J Hypertens. 2010;28:2316-22.
35. Delles C, Diez J, Dominiczak AF. Urinary proteomics in cardiovascular disease: Achievements, limits and hopes. Proteomics Clin Appl. 2011;5:222-32.
36. Mullen W, Gonzalez J, Siwy J, Franke J, Sattar N, Mullan A, et al. A pilot study on the effect of short-term consumption of a polyphenol rich drink on biomarkers of coronary artery disease defined by urinary proteomics. J Agric Food Chem. 2011;59:12850-7.
37. Donahue MP, Rose K, Hochstrasser D, Vonderscher J, Grass P, Chibout SD, et al. Discovery of proteins related to coronary artery disease using industrial-scale proteomics analysis of pooled plasma. Am Heart J. 2006;152:478-85. (Pubitemid 44233432)
38. Darde VM, de la Cuesta F, Dones FG, Alvarez-Llamas G, Barderas MG, Vivanco F. Analysis of the plasma proteome associated with acute coronary syndrome: does a permanent protein signature exist in the plasma of ACS patients? J Proteome Res. 2010;9:4420-32.
39. Jing L, Parker CE, Seo D, Hines MW, Dicheva N, Yu Y, et al. Discovery of biomarker candidates for coronary artery disease from an APOE-knock out mouse model using iTRAQ-based multiplex quantitative proteomics. Proteomics. 2011;11:2763-76.
40. Taurino C, Miller WH, McBride MW, McClure JD, Khanin R, Moreno MU, et al. Gene expression profiling in whole blood of patients with coronary artery disease. Clin Sci (Lond). 2010;119:335-43.
41. Salgado-Somoza A, Teijeira-Fernandez E, Fernandez AL, Gonzalez-Juanatey JR, Eiras S. Proteomic analysis of epicardial and subcutaneous adipose tissue reveals differences in proteins involved in oxidative stress. Am J Physiol Heart Circ Physiol. 2010;299:H202-9.
42. You SA, Archacki SR, Angheloiu G, Moravec CS, Rao S, Kinter M, et al. Proteomic approach to coronary atherosclerosis shows ferritin light chain as a significant marker: evidence consistent with iron hypothesis in atherosclerosis. Physiol Genomics. 2003;13:25-30. (Pubitemid 37129166)
43. Fortuno A, Olivan S, Beloqui O, San Jose G, Moreno MU, Diez J, et al. Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension. J Hypertens. 2004;22:2169-75. (Pubitemid 39463811)
44. Zalba G, Beloqui O, San Jose G, Moreno MU, Fortuno A, Diez J. NADPH oxidase-dependent superoxide production is associated with carotid intima-media thickness in subjects free of clinical atherosclerotic disease. Arterioscler Thromb Vasc Biol. 2005;25:1452-7. (Pubitemid 40923367)
45. Barderas MG, Tunon J, Darde VM, de la Cuesta F, Duran MC, Jimenez-Nacher JJ, et al. Circulating human monocytes in the acute coronary syndrome express a characteristic proteomic profile. J Proteome Res. 2007;6:876-86. (Pubitemid 46340192)
46. Delles C, Padmanabhan S, Lee WK, Miller WH, McBride MW, McClure JD, et al. Glutathione S-transferase variants and hypertension. J Hypertens. 2008;26:1343-52.
47. McBride MW, Brosnan MJ, Mathers J, McLellan LI, Miller WH, Graham D, et al. Reduction of Gstm1 expression in the stroke-prone spontaneously hypertension rat contributes to increased oxidative stress. Hypertension. 2005;45:786-92. (Pubitemid 40418382)
48. Wykrzykowska JJ, Garcia-Garcia HM, Goedhart D, Zalewski A, Serruys PW. Differential protein biomarker expression and their time-course in patients with a spectrum of stable and unstable coronary syndromes in the Integrated Biomarker and Imaging Study-1 (IBIS-1). Int J Cardiol. 2011;149:10-16.
49. Thongboonkerd V. Genomics, proteomics and integrative "omics" in hypertension research. Curr Opin Nephrol Hypertens. 2005;14:133-9. (Pubitemid 40396866)
50. Thongboonkerd V, Gozal E, Sachleben LR Jr, Arthur JM, Pierce WM, Cai J, et al. Proteomic analysis reveals alterations in the renal kallikrein pathway during hypoxia-induced hypertension. J Biol Chem. 2002;277:34708-16.
51. Reid JD, Holmes DT, Mason DR, Shah B, Borchers CH. Towards the development of an immuno MALDI (iMALDI) mass spectrometry assay for the diagnosis of hypertension. J Am Soc Mass Spectrom. 2010;21:1680-6.
52. Grussenmeyer T, Meili-Butz S, Roth V, Dieterle T, Brink M, Winkler B, et al. Proteome analysis in cardiovascular pathophysiology using Dahl rat model. J Proteomics. 2011;74:672-82.
53. Jin X, Xia L, Wang LS, Shi JZ, Zheng Y, Chen WL, et al. Differential protein expression in hypertrophic heart with and without hypertension in spontaneously hypertensive rats. Proteomics. 2006;6:1948-56.
54. Liu L, Wang W, Meng X, Gao J, Wu H, Wang P, et al. Left ventricular hypertrophy induced by abdominal aortic banding and its prevention by angiotensin receptor blocker telmisartan - a proteomic analysis. J Physiol Biochem. 2010;66:329-38.
55. Gallego-Delgado J, Lazaro A, Osende JI, Esteban V, Barderas MG, Gomez-Guerrero C, et al. Proteomic analysis of early left ventricular hypertrophy secondary to hypertension: modulation by antihypertensive therapies. J Am Soc Nephrol. 2006;17:S159-64. (Pubitemid 44865242)
56. Delbosc S, Haloui M, Louedec L, Dupuis M, Cubizolles M, Podust VN, et al. Proteomic analysis permits the identification of new biomarkers of arterial wall remodeling in hypertension. Mol Med. 2008;14:383-94.
57. Carty DM, Delles C, Dominiczak AF. Novel biomarkers for predicting preeclampsia. Trends Cardiovasc Med. 2008;18:186-94.
58. Carty DM, Delles C, Dominiczak AF. Preeclampsia and future maternal health. J Hypertens. 2010;28:1349-55.
59. Carty DM, Siwy J, Brennand JE, Zurbig P, Mullen W, Franke J, et al. Urinary proteomics for prediction of preeclampsia. Hypertension. 2011;57:561-9.
60. Blumenstein M, McMaster MT, Black MA, Wu S, Prakash R, Cooney J, et al. A proteomic approach identifies early pregnancy biomarkers for preeclampsia: novel linkages between a predisposition to preeclampsia and cardiovascular disease. Proteomics. 2009;9:2929-45.
61. Buhimschi IA, Zhao G, Funai EF, Harris N, Sasson IE, Bernstein IM, et al. Proteomic profiling of urine identifies specific fragments of SERPINA1 and albumin as biomarkers of preeclampsia. Am J Obstet Gynecol. 2008;199:551-16.
62. Chen G, Zhang Y, Jin X, Zhang L, Zhou Y, Niu J, et al. Urinary proteomics analysis for renal injury in hypertensive disorders of pregnancy with iTRAQ labeling and LC-MS/MS. Proteomics Clin Appl. 2011;5:300-10.
63. Rasanen J, Girsen A, Lu X, Lapidus JA, Standley M, Reddy A, et al. Comprehensive maternal serum proteomic profiles of preclinical and clinical preeclampsia. J Proteome Res. 2010;9:4274-81.
64. Araki Y, Nonaka D, Tajima A, Maruyama M, Nitto T, Ishikawa H, et al. Quantitative peptidomic analysis by a newly developed one-step direct transfer technology without depletion of major blood proteins: its potential utility for monitoring of pathophysiological status in pregnancy-induced hypertension. Proteomics. 2011;11:2727-37.
65. Zlatkovic J, Arrell DK, Kane GC, Miki T, Seino S, Terzic A. Proteomic profiling of KATP channel-deficient hypertensive heart maps risk for maladaptive cardiomyopathic outcome. Proteomics. 2009;9:1314-25.
66. Arrell DK, Zlatkovic LJ, Yamada S, Terzic A. K(ATP) channel-dependent metaboproteome decoded: systems approaches to heart failure prediction, diagnosis, and therapy. Cardiovasc Res. 2011;90:258-66.
67. V an Eyk JE. Overview: the maturing of proteomics in cardiovascular research. Circ Res. 2011;108:490-8.